Nanjing Well Materials Science and Technology Research Institute Co., Ltd. (referred to as “Institute”) is a wholly-owned subsidiary of Nanjing Well Pharmaceutical Group Co., Ltd (stock code: 603351). After over two decades of development, the Institute continuously focuses on the development and application research of pharmaceutical excipients, active pharmaceutical ingredients (APIs), medical polymer materials, lubricant materials, bio-based materials, health foods and animal health additives, etc. The institute has established a comprehensive, efficient and digitized research system encompassing centers of synthesis, quality research, scale-up and application evaluation. Innovative research and development (R&D) can provide technological supports for the development of the group's various business sectors.

Located in Nanjing Jiangbei New Materials Science and Technology Park, the Institute employs over 150 R&D professionals and has established joint laboratories with domestic research institutions and authoritative drug control institutes. It has built multiple national and provincial R&D platforms, including the NMPA Key Laboratory of Drug Preparation and Excipient Research and Evaluation (co-founded with China Pharmaceutical University’s Pharmaceutical Excipients and Generic/Innovative Drug R&D Evaluation Center and Jiangsu Institute for Drug Control), the JITRI-Well Pharmaceutical Group Joint Innovation Center (collaborating with Jiangsu Industrial Technology Research Institute), Provincial Engineering Technology Research Center, Foreign Expert Studio, the Jiangsu Postdoctoral Innovation Practice Base, and the Jiangsu Graduate Workstation. These platforms strongly support the Institute’s technological development, standard enhancement and application research of pharmaceutical excipients, empowering the company’s core competitiveness with innovative technologies and driving high-quality growth.

The Institute has undertaken multiple national and provincial scientific projects and contributed to drafting and revising the specifications of several excipients in the ChP and USP. Over 85 pharmaceutical excipients have been registered on Center for Drug Evaluation and more than 68 patents have been authorized. Several products have received honors such as the Second Prize of National Market Regulation Scientific Achievement Award and the Second Prize of Jiangsu Science and Technology Award.

In the future, the R&D Institute will constantly implement the group's corporate philosophy of "considering for you, helping you succeed ", continuously strengthen product innovation and do our best to assist customers in new drug application (NDA), abbreviated new drug application (ANDA) and Consistency Evaluation of Generic Drug. We are dedicated to deliver better customer service and wish to bring maximum benefits for all of our clients.